(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Manual for Instructive Application for Youngsters- 6 Spending plan 3D Printers with the Best Worth
- Immortal Style: Closet Staples for Each Age
- Surging measles cases are 'fire alarm' warning that other diseases could be next
- Extraordinary Shows to Long distance race on a Plane
- More people are addicted to marijuana, but fewer of them are seeking help, experts say
- A top Marine shares his secrets to keeping fit at 50
- Telecommute Arrangement: What's Vital for Your Efficiency?
- Compassion and Association: Building Significant Connections
